Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00390871 · ClinicalTrials.gov registry record · Phase 2

Acute Neurological ICU Sedation Trial (ANIST)

A Phase 2 study of Sedation, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT00390871 is a Phase 2 study of Sedation that has completed, run by Johns Hopkins University. The registered enrollment target is 35 participants, below the 100,183-participant average among 12 other Sedation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00390871, a Phase 2 study of Sedation, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.

Conditions Studied

Interventions

  • DRUG Fentanyl
  • DRUG Fentanyl/Dexmedetomidine
  • DRUG Fentanyl/Propofol

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2005-05
Est. Completion 2007-12
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT00390871

The ClinicalTrials.gov registry entry for NCT00390871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100,183-participant average among 12 other Sedation trials with a reported enrollment target (100% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sedation appearing as the primary indexed condition, and to 3 interventions - of which Fentanyl is the first listed.

NCT00390871 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00390871 about?

NCT00390871 is a clinical study titled "Acute Neurological ICU Sedation Trial (ANIST)". Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis,...

What is the current status of trial NCT00390871?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-05. Estimated completion is 2007-12.

What conditions does trial NCT00390871 study?

This clinical trial studies the following conditions: Sedation.

What interventions are being tested in trial NCT00390871?

The interventions under investigation include: Fentanyl (DRUG), Fentanyl/Dexmedetomidine (DRUG), Fentanyl/Propofol (DRUG).

Who is sponsoring clinical trial NCT00390871?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00390871 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sedation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.